Home » Pipeline
Pipeline
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| COVID-19 Trials and Actions | |||
| Laurent Pharmaceuticals | LAU-7b | hospitalized patients with COVID-19 | recruitment complete in phase 2 trial |
| Kintor Pharmaceutical | proxalutamide | hospitalized patients with COVID-19 | approval received from the FDA to proceed with a phase 3 trial |
| LabCorp | Pixel COVID-19 PCR test home collection kit for ages two to 17 | COVID-19 test | Emergency Use Authorization (EUA) granted by the FDA |
| Roche | Cobas SARS-CoV-2 test | asymptomatic COVID-19 testing | EUA granted by the FDA |
| Other Trials and Actions | |||
| GammaDelta Therapeutics | GDX012 | hematological malignancies | IND approved by the FDA |
| ImmunityBio | m-ceNK platform combined with Anktiva (N-803) | locally advanced or metastatic solid tumors | IND approved by the FDA |
| DiaMedica | DM199 (recombinant human tissue kallikrein-1or KLK1) | acute ischemic stroke | IND approved by the FDA for a phase 2/3 trial |
| PharmaTher Holdings | ketamine | levodopa-induced dyskinesia in patients with Parkinson’s disease | IND approved by the FDA for a phase 2 trial |
| Propella Therapeutics | PRL-02 (abiraterone decanoate) | metastatic prostate cancer | IND approved by the FDA |
| InnoCare | oral ICP-332 | autoimmune diseases | IND approved by China's National Medical Products Administration |
| Altasciences SiteOne Therapeutics |
ST-2427 | management of moderate-to-severe pain | initiation of phase 1 trial |
| Crescendo Biologics | CB307 | patients with advanced and/or metastatic PSMA-positive solid tumors | first patient enrolled in phase 1 trial |
| GoldFinch Bio | GFB-024 | severe insulin-resistant diabetic nephropathy | first patients dosed in phase 1 trial |
| Mustang Bio City of Hope |
MB-101 (autologous IL13R?2-CAR T cells) | leptomeningeal brain tumors (e.g., glioblastoma, ependymoma or medulloblastoma) | first patients dosed in phase 1 trial |
| Pyramid Biosciences | PBI-100 | mild-to-moderate psoriasis | first patients dosed in phase 1 trial |
| Catalyst Biosciences | marzeptacog alfa (activated); MarzAA | bleeding in FVII deficiency, Glanzmann thrombasthenia and hemophilia A with inhibitor patients receiving Hemlibra prophylaxis | first patient dosed in phase 1/2 trial |
| GeneTx Biotherapeutics Ultragenyx Pharmaceuticals |
intrathecally administered GTX-102 | Angelman syndrome | clearance from Health Canada to initiate phase 1/2 trial |
| Xalud Therapeutics | XT-150 | patients with radicular neuropathic pain due to lumbar disc disease | first patient dosed in phase 1/2a trial |
| Galera Therapeutics | GC4711 in combination with stereotactic body radiation therapy (SBRT) | locally advanced pancreatic cancer | first patient dosed in phase 2b trial |
| Xalud Therapeutics | XT-150 | moderate-to-severe pain due to osteoarthritis of the knee | recruitment complete in phase 2b trial |
| Endogena Therapeutics | EA-2353 ophthalmic suspension | retinitis pigmentosa | Orphan Drug designation granted by the FDA |
| GammaDelta Therapeutics | GDX012 | acute myeloid leukemia | Orphan Drug designation granted by the FDA |
| Bridge BioPharma | BBP-631 | congenital adrenal hyperplasia | Fast-Track designation granted by the FDA |
| Palisade Bio | LB1148 | reduction of adhesions following abdominal or pelvic surgery | Fast-Track designation granted by the FDA |
| Apellis Pharmaceuticals | Empaveli (pegcetacoplan) | adults with paroxysmal nocturnal hemoglobinuria | approved by the FDA |
Upcoming Events
-
24May
-
25May
-
28Jun
-
16Oct
